| 科室始建于1971年，称为科研生化室，1982年张克勤任科主任，1987年黄建英任科主任，1999年与分子生物学室合并为生物化学与分子生物学研究室，2000年至今冯玉梅任科主任。作为研究型科室，致力于在“研究的创新性”和“研究成果的应用性”两个方面谋求发展。“研究的创新性”方面，在“乳腺癌转移预后预测和转移机制研究”方向上，筛选新的乳腺癌转移关键基因，并阐明其在乳腺癌转移中的作用机制，以及在乳腺癌预后预测和抗转移治疗中的临床价值；“研究成果的应用性”方面，充分利用研究型科室的技术和设备优势，围绕临床个体化诊断和治疗的需求，将科研成果转化为临床基因诊断项目，实现科研成果的社会效益。
科室建设的“临床基因扩增(PCR)检验实验室”获卫生部临床检验中心认证(2008年)和天津市临床检验中心的复审(2014年)。目前开展的系列临床基因诊断项目包括：1)肿瘤相关病毒/病菌定量基因诊断，2)循环肿瘤细胞和肿瘤微转移定量基因诊断，3)肿瘤化疗药物敏感性基因诊断，4)肿瘤分子靶向治疗药物敏感性基因诊断，5)肿瘤生物学特性和预后评估基因诊断等。这些项目的临床应用可为肿瘤发生的病因学诊断、提高肿瘤分期的准确性、评估患者预后、动态监测化疗疗效、预测分子靶向治疗敏感性、指导个体化治疗提供客观依据。
“严谨，求是，创新”是科室建设和发展一贯遵循的理念。
·Team Members
Yu-Mei Feng, Ph.D., director and professor, research projects focus on molecular mechanism of breast cancer metastasis and gene-based diagnosis for malignant tumors.
Other staffs and students including 3 researchers Xiao-Qing Li (MD, PhD), Qing-Shan Wang (MD, PhD) and Rui Zhang (PhD), 2 technicians and about 7 Ph.D. or M.S. graduate students.
·Research projects
1. The role and mechanism of FOXF2 in inhibiting basal-like breast cancer lymphangiogenic mimicry, supported by the National Natural Science Foundation of China (No. 81773125), 2018.1-2021.12
2. The role and mechanism of FOXF2 in regulating breast cancer bone metastasis, supported by the National Natural Science Foundation of China (No. 81672894), 2017.1-2020.12
3. Breast cancer CDH11+/ITGA5+ exosomes initiated the RUNX2-driven pre-metastatic niche formation in the bone, supported by the National Natural Science Foundation of China (No. 81672878), 2017.1-2020.12
4. The role and mechanism of FOXF2 in regulating activation of stromal fibroblasts in breast cancer microenvironment, supported by the National Natural Science Foundation of China (No. 81472680), 2015.1-2018.12
5. FOXF2 suppresses basal-like breast cancer metastasis by negatively regulating EMT-associated transcription factors, supported by the Major Program of Applied Basic Research Projects of Tianjin (No. 13JCZDJC30100), 2013.4 -2016.3
6. The role and mechanism of FOXF2 in basal-like breast cancer metastasis, supported by the National Natural Science Foundation of China (No. 81272357), 2013.1-2016.12
7. The role of FOXF2 transcription factor in breast cancer metastasis via regulating VEGF-C/VEGFR3 signaling in tumor microenviroment, supported by the National Natural Science Foundation of China (No. 81201652), 2013.1-2015.12
8. Key role of Smads-RUNX2 complex in bone metastasis of breast cancer mediated by RUNX2, supported by the National Natural Science Foundation of China (No. 81201647), 2013.1-2015.12
9. The role and mechanism of microtubule motor protein KIF22/Kid in proliferation of breast cancer cells by interacting with Aurora-B kinase, supported by the National Natural Science Foundation of China (No. 31201030), 2013.1-2015.12
10. Molecular mechanisms of RUNX2 facilitating chemoattractant and adhesion of breast cancer cells to bone, supported by The Specialized Research Fund for the Doctoral Program of Higher Education (No. 2012202120011), 2013.1-2015.12
11. Study of microtubule motor protein Kid interacting with Aurora-B kinase and regulating the cell proliferation in breast cancer and its molecular mechanism, supported by The Specialized Research Fund for the Doctoral Program of Higher Education (No. 2012202120012), 2013.1-2015.12
12. Study on the functions and mechanism of ITGBL1 in bone metastasis of breast cancer, supported by the Major Program of Applied Basic Research Projects of Tianjin (No. 09JCZDJC19800), 2009.4-2012.3
13. Study on the functions and mechanism of ITGBL1 in bone metastasis of breast cancer, supported by the National Natural Science Foundation of China (No. 30872518), 2009.1-2011.12
14. Optimization of gene markers and establishment of predictive model for molecular diagnosis of breast cancer prognosis, supported by the Applied Basic Research Projects of Tianjin (No. 06YFJMJC12900), 2006.9-2009.8
15. The mechanism of KNSL4/KIF22 involved in metastasis of breast cancer, supported by the National Natural Science Foundation of China (No. 30471671), 2005.1-2008.12
·Published articles (*Corresponding author)
1. Wang QS, He R, Yang F, Kang LJ, Li XQ, Fu L, Sun B*, Feng YM*. FOXF2 deficiency permits basal-like breast cancer cells to form lymphangiogenic mimicry by enhancing the response of VEGF-C/VEGFR3 signaling pathway. Cancer Lett. 2018, 420:116-126.
2. Yu ZH#, Lun SM#, He R#, Tian HP, Huang HJ, Wang QS, Li XQ, Feng YM*. Dual Function of MAZ Mediated by FOXF2 in Basal-like Breast Cancer: Promotion of Proliferation and Suppression of Progression. Cancer Lett. 2017, 402:142-152.
3. Tan CC#, Li GX#, Tan LD, Du X, Li XQ, He R, Wang QS, Feng YM*. Breast cancer cells obtain an osteomimetic feature via epithelial-mesenchymal transition that has undergone BMP2/RUNX2 signaling pathway induction. Oncotarget. 2016, 7(48):79688-79705.
4. Li XQ, Lu JT, Tan CC, Wang QS, Feng YM*. RUNX2 promotes breast cancer bone metastasis by increasing integrin α5-mediated colonization. Cancer Lett. 2016;380(1):78-86.
5. Cai J, Tian AX, Wang QS, Kong PZ, Du X, Li XQ, Feng YM*. FOXF2 suppresses the FOXC2-mediated epithelial-mesenchymal transition and multidrug resistance of basal-like breast cancer. Cancer Lett. 2015, 367(2):129-37.
6. Li XQ, Du X, Li DM, Kong PZ, Sun Y, Liu PF, Wang QS, Feng YM*. ITGBL1 Is a Runx2 Transcriptional Target and Promotes Breast Cancer Bone Metastasis by Activating the TGFβ Signaling Pathway. Cancer Res. 2015, 75(16): 3302-3313.
7. Tian HP, Lun SM, Huang HJ, He R, Kong PZ, Wang QS, Li XQ, Feng YM*. DNA Methylation Affects the SP1-regulated Transcription of FOXF2 in Breast Cancer Cells. J Biol Chem. 2015;290(31):19173-83.
8. Wang QS, Kong PZ, Li XQ, Yang F, Feng YM*. FOXF2 deficiency promotes epithelial-mesenchymal transition and metastasis of basal-like breast cancer. Breast Cancer Res. 2015;17:30.
9. Yu Y, Xiao CH, Tan LD, Wang QS, Li XQ, Feng YM*. Cancer-associated fibroblasts induce epithelial-mesenchymal transition of breast cancer cells through paracrine TGF-β signalling. Br J Cancer. 2014;110(3):724-732.
10. Yu Y, Wang XY, Sun L, Wang YL, Wan YF, Li XQ, Feng YM*. Inhibition of KIF22 Suppresses Cancer Cell Proliferation by Delaying Mitotic Exit through Up-regulating CDC25C Expression. Carcinogenesis. 2014;35(6):1416-1425.
11. Du X, Li XQ, Li L, Xu YY, Feng YM*. The detection of ESR1/PGR/ERBB2 mRNA levels by RT-QPCR: a better approach for subtyping breast cancer and predicting prognosis. Breast Cancer Res Treat. 2013;138(1):59-67.
12. Kong PZ, Yang F, Li L, Li XQ, Feng YM*. Decreased FOXF2 mRNA Expression Indicates Early-Onset Metastasis and Poor Prognosis for Breast Cancer Patients with Histological Grade II Tumor. PLoS One. 2013; 2013;8(4):e61591.
13. Ge J#, Tian AX#, Wang QS, Kong PZ, Yu Y, Li XQ, Cao XC, Feng YM*. The GSTP1 105Val Allele Increases Breast Cancer Risk and Aggressiveness but Enhances Response to Cyclophosphamide Chemotherapy in North China. PLoS One. 2013;8(6):e67589.
14. Li XQ, Li L, Xiao CH, Feng YM*. The expression level of NEFL mRNA is a prognostic factor for breast cancer. PLoS One. 2012;7(2):e31146.
15. Li DM, Feng YM*. Signaling Mechanism of Cell Adhesion Molecules in Breast Cancer Metastasis: Potential Therapeutic Targets. Breast Cancer Res Treat. 2011;128(1):7-21.
16. Tan LD#, Xu YY#, Yu Y, Li XQ, Chen Y, Feng YM*. Serum HER2 Level Measured by Dot Blot: a Valid and Inexpensive Assay for Monitoring Breast Cancer Progression. PLoS One. 2011;6(4):e18764.
17. Chen XH, Li XQ, Chen Y, Feng YM*. Risk of Aggressive Breast Cancer in Women of Han Nationality Carrying TGFB1 rs1982073 C Allele and FGFR2 rs1219648 G allele in North China. Breast Cancer Res Treat. 2011;125(2):575-582.
18. Yu Y, Feng YM*. The Role of Kinesin Family Proteins in Tumorigenesis and Progression: Potential Biomarkers and Molecular Targets for Cancer Therapy. Cancer. 2010;116(22):5150-5160.
19. Li X, Liu J, Wang Y, Zhang L, Ning L, Feng Y*. Parallel Underexpression of KLK5 and KLK7 mRNA in Breast Malignancies. Cancer Sci. 2009;100(4):601-607.
20. Li X, Cao X, Li X, Zhang W, Feng Y*. Expression level of insulin-like growth factor binding protein 5 mRNA is a prognostic factor for breast cancer. Cancer Sci. 2007;98(10):1592-1596.
·Gene-based diagnosis for clinical application
Purpose of the diagnosis: To diagnose the etiology of carcinogenesis; to enhance the accuracy of tumor clinical staging; to evaluate the prognosis of patients; to dynamically supervise the effect of therapy; to estimate the response to chemotherapy, endocrine therapy and molecular targeted therapy; and to guide the individualized treatment.
Medical administrative license: the “Clinical Gene Amplification (PCR) Testing” in Tianjin Cancer Institute and Hospital was approved by Tianjin Public Health Bureau.
Qualification of the laboratory: the “Clinical Gene Amplification (PCR) Testing Laboratory” was certificated by the National Center for Clinical Laboratory.
Qualification of the staff: Dr. Xiao-Qing Li, Dr. Qing-Shan Wang, Dr. Rui Zhang, Ms. Kun Zhao and Ms. Ning Sun are qualified for “Clinical Gene Amplification (PCR) Testing” by the National Center for Clinical Laboratory.
·Gene-based PCR and sequence assays:
·Detection of tumor associated virus and bacteria
HPV-DNA
EBV-DNA
HBV-DNA
HCV-RNA
HCMV-DNA
HP-DNA
·Specific markers and intrinsic characteristics of cancer
Breast cancer susceptibility gene: BRCA1, BRCA2
Prostate cancer: PCA3, PSA, TMPRSS2-ERG, AMACR
Thyroid: BRAF, RET
Leukemia: BCR-ABL, PML-RARα
Melanoma: BRAF
Gliomas: MGMT
Tumor proliferation: Ki-67
·Detection of micrometastasis
Epithelial tumor: CK19, CEA
·Estimation of response to chemotherapy
Alkaloids, Anthracycline, VP-16, Paclitaxel: MDR1
Paclitaxel, Vinblastine: TUBB3, BRCA1
Platinum: BRCA1, ERCC1, XRCC1, XPD, GSTP1
Gemcitabine: RRM1
5-FU, Pemetrexed: TYMS, MTHFR, DPDY
Irinotecan: UGT1A1
mercaptopurine, Azathioprine, 6-thioguanine: TPMT
·Estimation of response to endocrine therapy
Tamoxifen, Aminoglutethimide: ER, PR
·Estimation of response to molecular targeted therapy
Trastuzumab (Herceptin): HER2
Imatinib (Gleevec): C-Kit, BCR-ABL, PDGFR A, PDGFRB
Sunitinib (Sutent): C-Kit, VEGFR1, VEGFR2, PDGFRA, PDGFRB
Gefitinib (Iressa), Erlotinib (Tarceva) : EGFR, K-RAS
Cetuximab (Erbitux), Panitumumab (Vectibix) : K-RAS, BRAF
Bevacizumab (Avastin), Endostatin (Endostar) : VEGFR1, VEGFR2
|
